Head-To-Head Comparison: PTC Therapeutics (NASDAQ:PTCT) versus GeoVax Labs (NASDAQ:GOVX)

GeoVax Labs (NASDAQ:GOVX) and PTC Therapeutics (NASDAQ:PTCT) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and valuation.

Valuation & Earnings

This table compares GeoVax Labs and PTC Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$2.49 million	0.35	-$21.47 million	($11.34)	-0.15
PTC Therapeutics	$1.73 billion	3.06	$682.64 million	($1.40)	-45.35

PTC Therapeutics has higher revenue and earnings than GeoVax Labs. PTC Therapeutics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

GeoVax Labs has a beta of 3.85, suggesting that its share price is 285% more volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for GeoVax Labs and PTC Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	1	1	1	0	2.00
PTC Therapeutics	1	3	10	1	2.73

GeoVax Labs presently has a consensus price target of $3,600.00, suggesting a potential upside of 210,426.32%. PTC Therapeutics has a consensus price target of $99.23, suggesting a potential upside of 56.29%. Given GeoVax Labs’ higher possible upside, equities research analysts plainly believe GeoVax Labs is more favorable than PTC Therapeutics.

Profitability

This table compares GeoVax Labs and PTC Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-901.14%	-392.27%
PTC Therapeutics	-9.17%	N/A	-0.10%

Institutional & Insider Ownership

6.1% of GeoVax Labs shares are owned by institutional investors. 0.2% of GeoVax Labs shares are owned by company insiders. Comparatively, 5.3% of PTC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

PTC Therapeutics beats GeoVax Labs on 10 of the 15 factors compared between the two stocks.

About GeoVax Labs

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer. The company’s technology platform is based primarily on modified vaccinia Ankara (MVA) and virus-like particle (VLP) vaccine technologies, which are designed to generate broad and durable immune responses. GeoVax’s pipeline has included GEO-CM04S1, a multivalent COVID-19 vaccine candidate intended to address emerging coronavirus variants, as well as investigational vaccines for HIV, hemorrhagic fever viruses such as Ebola and Marburg, and other infectious diseases.

About PTC Therapeutics

PTC Therapeutics is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Founded in 1998 and headquartered in Warren, New Jersey, the company works across several therapeutic areas, including genetic and neurological disorders. Its products include Kebilidi (eladocagene exuparvovec), a gene therapy for aromatic L-amino acid decarboxylase deficiency, and Sephience (sepiapterin), a treatment for phenylketonuria. PTC has also developed medicines for Duchenne muscular dystrophy, including ataluren, marketed as Translarna in some regions.